Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784531 · ClinicalTrials.gov registry record · NA
The Influence of Race and MitoQ Supplementation on Skin Blood Flow in the Cold
A NA study of Cold Exposure, sponsored by United States Army Research Institute of Environmental Medicine.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06784531: Active NA study of Cold Exposure, sponsored by United States Army Research Institute of Environmental Medicine.
NCT06784531 is a NA study of Cold Exposure that is active but no longer recruiting, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 30 participants, below the 56-participant average among 3 other Cold Exposure trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06784531, a NA study of Cold Exposure, is active but no longer recruiting, sponsored by United States Army Research Institute of Environmental Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals who operate in cold weather are at risk of developing cold injuries, for example, frostbite. They also often experience a loss of hand function and joint mobility due to a decrease in skin temperature and blood flow. In addition, the risk of getting a cold injury is higher in the Black population compared to other racial and ethnic groups. Increases in oxidant compounds can cause the blood vessels in the skin to narrow and decrease skin temperature in the cold. However, it is unknown whether the higher risk of cold injury in Black individuals is because of a greater amount of oxidant compounds in the blood vessels. The purpose of this research is to see if an antioxidant supplement called MitoQ can help to improve skin temperature and blood flow in the cold and if the improvement is greater in Black individuals.
Primary Outcome
Skin blood flow is measured on the arm, hand, and finger using non-invasive laser probes. Output (red blood cell flux) will be divided by mean arterial blood pressure to give an index of cutaneous vascular conductance \[CVC, flux/mmHg\].
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Mitoquinone mesylate (MitoQ)
- OTHER Cold Water Hand Immersion
- OTHER Cold Air Exposure
Study Locations (1)
Massachusetts
- U.S. Army Research Institute of Environmental Medicine - Natick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-01 |
| Phase | NA |
What the registry record for NCT06784531 still lists
NCT06784531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 56-participant average among 3 other Cold Exposure trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Cold Exposure appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06784531 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06784531 about?
NCT06784531 is a clinical study titled "The Influence of Race and MitoQ Supplementation on Skin Blood Flow in the Cold". Individuals who operate in cold weather are at risk of developing cold injuries, for example, frostbite. They also often experience a loss of hand function and joint mobility due to a decrease in skin temperature and blood flow. In addition, the risk of getting a cold injury is higher in the Black ...
What is the current status of trial NCT06784531?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-16. Estimated completion is 2026-01.
What conditions does trial NCT06784531 study?
This clinical trial studies the following conditions: Cold Exposure.
What interventions are being tested in trial NCT06784531?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Mitoquinone mesylate (MitoQ) (DIETARY_SUPPLEMENT), Cold Water Hand Immersion (OTHER), Cold Air Exposure (OTHER).
Who is sponsoring clinical trial NCT06784531?
This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784531 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cold Exposure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI